China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a pharmaceutical company that specializes in the development and manufacture of various pharmaceutical products. The company has been involved in the healthcare sector, primarily focusing on the production and marketing of medicines to improve health outcomes.

CCI Score

-13.49

0.01% April 29

Latest Event

Enhanced Anti-Corruption Compliance Guidelines Impact on Pharma Sector

On January 2025, China's State Administration for Market Regulation issued new Compliance Guidelines aimed at preventing commercial bribery in the healthcare sector, suggesting that pharmaceutical companies, including China Pharma Holdings, may need to bolster their internal anti-corruption programs to meet rising regulatory expectations.

Take Action

So what can you do? It's time to make tough choices. Where will you cast your vote?

Shop Alternatives SEE ALL: Almirall

Kaken

Novo Nordisk
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

ENABLER

China Pharma Holdings, Inc. is currently rated as an Enabler.

-10 to -19 CCI Score

Companies in this segment facilitate authoritarian practices while claiming neutrality. They provide resources or support that indirectly bolster oppressive regimes, thereby undermining democratic accountability without overtly endorsing the regime.

Latest Events

JAN

23

2025

Enhanced Anti-Corruption Compliance Guidelines Impact on Pharma Sector
48.69

On January 2025, China's State Administration for Market Regulation issued new Compliance Guidelines aimed at preventing commercial bribery in the healthcare sector, suggesting that pharmaceutical companies, including China Pharma Holdings, may need to bolster their internal anti-corruption programs to meet rising regulatory expectations.
+50

Business Practices and Ethical Responsibility

April 7

The new Compliance Guidelines represent a positive shift toward transparency and ethical business practices in the healthcare sector. By mandating robust anti-corruption measures, regulators are pushing companies to adhere to international best practices, thereby promoting corporate accountability and reducing the risk of corrupt practices that can underpin authoritarian behaviors. This regulatory action is viewed positively from an anti-fascist perspective as it strives to dismantle opaque and unethical practices.

China Tightens the Reins: Anti-Corruption Compliance Expectations for Companies in the Healthcare Sector
OCT

08

2024

Allegations of Forced Labor in Pharmaceutical Supply Chains
-75.66

A C4ADS report has highlighted forced labor practices in the Xinjiang Uyghur Autonomous Region affecting global pharmaceutical supply chains. Although China Pharma Holdings, Inc. is not explicitly named, the findings raise concerns over unethical sourcing practices in the broader pharmaceutical industry.
-80

Supply Chain Ethics

April 7

The report details the exploitation of forced labor in Xinjiang, linking a number of pharmaceutical products to these unethical practices. While China Pharma Holdings is not directly implicated, companies operating in this space face risks of being connected to such supply chain issues, which undermine human rights and ethical business practices.

Pharmaceutical Supply Chains Tied to Forced Labor in Uyghur Region, Report Finds